argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company focuses on developing product candidates with the potential...Show all
Company (Alive / Active)
Phone: +31 763 030 488
Breda,
Netherlands
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Garp-tgf-beta 1 antibodies | May 10, 2019 | Dec 29, 2020 | Patent |
Garp-tgf-beta 1 antibodies | Nov 27, 2019 | Oct 06, 2020 | Patent |
Anti-il-22r antibodies | Jan 08, 2019 | Jun 30, 2020 | Patent |
Anti c-met antibodies | Dec 26, 2017 | Jun 09, 2020 | Patent |
Anti-garp protein and uses thereof | May 09, 2018 | Mar 31, 2020 | Patent |